Affiliation:
1. Department of Cardiothoracic Surgery, The First People’s Hospital of Neijiang, Neijiang, Sichuan, China.
Abstract
Background:
To further identify the association between the lymph node micrometastasis (LNM) and long-term survival among pN0 esophageal cancer patients receiving the surgery.
Methods:
Several databases were searched for relevant studies up to June 22, 2023. The primary and secondary outcomes were separately overall survival (OS) and relapse-free survival (RFS) and hazard ratios (HRs) with 95% confidence intervals (CIs) were combined. Subgroup analysis based on pathological type and source of HR was further performed. All statistical analyses were conducted by STATA 15.0 software.
Results:
A total of 20 studies involving 1830 pN0 patients were included in this meta-analysis. The pooled results demonstrated that the presence of LNM indicated significantly worse OS (HR = 2.19, 95% CI = 1.77–2.70, P < .001) and RFS (HR = 2.15, 95% CI = 1.65–2.80, P < .001). Besides, subgroup analysis for the OS and RFS stratified by the pathological type (squamous cell carcinoma vs mixed esophageal cancer) and source of HR (reported vs estimated) further identified the significant relationship of LNM with prognosis in surgical esophageal cancer.
Conclusion:
The presence of LNM indicated significantly poorer long-term survival among operated pN0 esophageal cancer patients. LNM could serve as a novel and reliable prognostic indicator in surgical esophageal cancer.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference47 articles.
1. Cancer statistics in China and United States, 2022: profiles, trends, and determinants.;Xia;Chin Med J (Engl),2022
2. Cancer statistics in Chinese older people, 2022: current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea.;Ju;Sci China Life Sci,2023
3. [Cancer statistics in China, 2016].;Zheng;Zhonghua Zhong Liu Za Zhi,2023
4. Surgical intervention after neoadjuvant therapy in esophageal cancer: a narrative review.;Ke;J Thorac Dis,2023
5. Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis.;Wang;Front Immunol,2023